Proteflazid® and local immunity in diseases caused by human papillomavirus, herpesvirus and mixed urogenital infections.
Reporting of clinical trials results for Proteflazid® in the drug formulation suppositories and vaginal swabs soaked in the solution of the drug to the local immunity of the female reproductive tract.


OBJECTIVE
The aim of study was to examine the state of local immunity in the reproductive tract of women with sexually transmitted diseases caused by human papillomavirus, herpes viruses (Type 1, 2) and mixed infection (herpes viruses + chlamydia).


METHODS
The trials involved 216 women with viral sexually transmitted diseases: Cervical Dysplasia associated with papillomavirus infection (HPV) (Group 1); Herpes genitalis type 1 (HSV- 1) and type 2 (HSV-1) (Group 2); mixed infection - HSV-1, HSV-2 and chlamydia (Group 3).


RESULTS
Treatment results have confirmed that Proteflazid® contributes to sustainable performance improvement of basic factors of local immunity - sIgA, lysozyme and complement component C3 in the cervical mucus for all three groups of women.


CONCLUSIONS
Proteflazid® enhances level of local immunity markers (sIgA, lysozyme, C3 complement component) and improves their ratios. Also it intensifies anticontagious activity of mucosal protection and female reproductive system as whole, during treatment diseases caused by human papillomavirus, herpesvirus and mixed urogenital infections (herpesvirus and chlamydia).
Shupyk National Medical Academy for Post-graduate Education, Kyiv, Ukraine.
Vjacheslav
V
Kaminsky
State Institution "Institute of Pediatrics, Obstetrics and Gynecology of NAMS of Ukraine", Kyiv; Ukraine.
Viktor
V
Chernyshov
Scientific & Manufacturing Company "Ecopharm" Ltd, Kyiv, Ukraine.
Oleksandr
O
Grynevych
Bogomolets National Medical University, Kyiv, Ukraine.
Vasil
V
Benyuk
State Institution "Institute of Pediatrics, Obstetrics and Gynecology of NAMS of Ukraine", Kyiv; Ukraine.
Alla
A
Kornatskaya
Shupyk National Medical Academy for Post-graduate Education, Kyiv, Ukraine.
Miroslava
M
Shalko
Bogomolets National Medical University, Kyiv, Ukraine.
Igor
I
Usevich
State Institution "Institute of Pediatrics, Obstetrics and Gynecology of NAMS of Ukraine", Kyiv; Ukraine.
Oleg
O
Revenko
Scientific & Manufacturing Company "Ecopharm" Ltd, Kyiv, Ukraine.
Maxim
M
Shepetko
Scientific & Manufacturing Company "Ecopharm" Ltd, Kyiv, Ukraine.
Ludmila
L
Solomakha
D002690:Chlamydia Infections / Q000188:drug therapy*; D060085:Coinfection / Q000188:drug therapy* / Q000382:microbiology / Q000821:virology; D005260:Female; D052776:Female Urogenital Diseases / Q000188:drug therapy / Q000382:microbiology / Q000821:virology; D006566:Herpesviridae Infections / Q000188:drug therapy*; D018259:Herpesvirus 1, Human / Q000187:drug effects; D018258:Herpesvirus 2, Human / Q000187:drug effects; D006801:Humans; D007107:Immune System / Q000187:drug effects*; D027383:Papillomaviridae / Q000187:drug effects; D030361:Papillomavirus Infections / Q000188:drug therapy*; D010936:Plant Extracts / Q000494:pharmacology / Q000627:therapeutic use*; D010946:Plants, Medicinal; D006109:Poaceae; D012749:Sexually Transmitted Diseases / Q000188:drug therapy* / Q000382:microbiology / Q000821:virology; D016896:Treatment Outcome
D010936:Plant Extracts
Proteflazid®; herpes; local immunity; mixed infection; papillomavirus